Abbott Laboratories Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD 8.95 B

Abbott Laboratories Operating Cash Flow is USD 8.95 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 25.30% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Abbott Laboratories Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 7.14 B, a -17.51% change year over year.
  • Abbott Laboratories Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 8.66 B, a -13.07% change year over year.
  • Abbott Laboratories Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 9.96 B, a 1.40% change year over year.
  • Abbott Laboratories Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 9.82 B, a 60.01% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities